Aurum Insights–Pharmaceuticals
October 2014
Dear Reader‚

Aurum Equity Partners LLP is delighted to introduce our quarterly newsletter‚ which will provide updates‚ insights and perspectives on the pharmaceutical sector in India.


Click here to download the Newsletter


We believe you will find the information useful and relevant.

Do let us know if you would like to share your insights and perspectives‚ we would attempt to incorporate them in our future Newsletters.

If you have any suggestions on what we could include‚ please write to me or to our Knowledge Services team at ritikasingh@aurumequity.com.

Regards

Sanjay Bansal
Founder– Aurum Equity Partners LLP
sanjaybansal@aurumequity.com
In this issue
  • The prospects of the Global generics market are looking bright over the next few years‚ given the pro–generic environment in developed markets‚ rising utilization levels‚ patent expiries and growing Government role in providing healthcare in emerging markets

  • The overseas markets represent a large opportunity and many Indian companies like Sun‚ Lupin‚ Cipla‚ Zydus‚ Torrent have been expanding their presence over the past few years

  • The recent deals over the past 6–12 months does indicate Indian Pharma companies’ aggressive plans to build a global pharma franchise and we expect many more Indian companies to emerge as global leaders in the fast growing generic market

Aurum Equity Partners LLP

Trusted investment bankers for mergers & acquisitions‚ fundraising and restructuring.

www.aurumequity.com
Subscribe to Aurum mailers Email to Aurum Visit the Aurum website
Click here to Unsubscribe from this mailer.